146 related articles for article (PubMed ID: 37366901)
1. Estimating the Associated Burden of Illness and Healthcare Utilization of Newly Diagnosed Patients Aged ≥65 with Mantle Cell Lymphoma (MCL) in Ontario, Canada.
Anglin P; Elia-Pacitti J; Eberg M; Muratov S; Kukaswadia A; Sharma A; Ewara EM
Curr Oncol; 2023 Jun; 30(6):5529-5545. PubMed ID: 37366901
[TBL] [Abstract][Full Text] [Related]
2. Treatment patterns, adverse events, healthcare resource use and costs among commercially insured patients with mantle cell lymphoma in the United States.
Kabadi SM; Near A; Wada K; Burudpakdee C
Cancer Med; 2019 Dec; 8(17):7174-7185. PubMed ID: 31595715
[TBL] [Abstract][Full Text] [Related]
3. Adverse Events and Economic Burden Among Patients Receiving Systemic Treatment for Mantle Cell Lymphoma: A Real-World Retrospective Cohort Study.
Kabadi SM; Byfield SD; LE L; Olufade T
Anticancer Res; 2021 Feb; 41(2):927-936. PubMed ID: 33517299
[TBL] [Abstract][Full Text] [Related]
4. Treatment Patterns Among Patients With Mantle Cell Lymphoma and Comparison of Healthcare Resource Utilization and Costs Among Relapsed/Refractory Patients Treated With Ibrutinib or Chemoimmunotherapy: A Real-world Retrospective Study.
Ghosh N; Emond B; Lafeuille MH; Côté-Sergent A; Lefebvre P; Huang Q
Clin Ther; 2021 Aug; 43(8):1285-1299. PubMed ID: 34332789
[TBL] [Abstract][Full Text] [Related]
5. Assessing unmet need among elderly Medicare Beneficiaries with Mantle cell lymphoma: an analysis of treatment patterns, survival, healthcare resource utilization, and costs.
Squires P; Puckett J; Ryland KE; Kamal-Bahl S; Raut M; Doshi JA; Huntington SF
Leuk Lymphoma; 2023; 64(11):1752-1770. PubMed ID: 37497877
[TBL] [Abstract][Full Text] [Related]
6. Bendamustine Plus Rituximab for Mantle Cell Lymphoma: A Korean, Multicenter Retrospective Analysis.
Yi JH; Kim SJ; Lee JO; Lee GW; Kwak JY; Eom HS; Jo JC; Choi YS; Oh SY; Kim WS
Anticancer Res; 2022 Dec; 42(12):6083-6089. PubMed ID: 36456154
[TBL] [Abstract][Full Text] [Related]
7. Real-world evidence on survival, adverse events, and health care burden in Medicare patients with mantle cell lymphoma.
Goyal RK; Jain P; Nagar SP; Le H; Kabadi SM; Davis K; Kaye JA; Du XL; Wang M
Leuk Lymphoma; 2021 Jun; 62(6):1325-1334. PubMed ID: 33966583
[TBL] [Abstract][Full Text] [Related]
8. Comparative Effectiveness of Chemotherapy, Rituximab, and Bendamustine in Medicare Beneficiaries With Mantle-Cell Lymphoma.
Fu S; Wang M; Zhao H; Li R; Lairson DR; Giordano SH; Zhao B; Du XL
Clin Lymphoma Myeloma Leuk; 2019 Nov; 19(11):e616-e623. PubMed ID: 31563564
[TBL] [Abstract][Full Text] [Related]
9. Health resource utilization and costs of care for adult patients with relapsed or refractory mantle cell lymphoma in the United States: a retrospective claims analysis.
Ito D; Feng C; Fu C; Kim C; Wu J; Epstein J; Snider JT; DuVall AS
Expert Rev Pharmacoecon Outcomes Res; 2023; 23(7):773-787. PubMed ID: 37278284
[TBL] [Abstract][Full Text] [Related]
10. Bendamustine and rituximab as induction therapy in both transplant-eligible and -ineligible patients with mantle cell lymphoma.
Villa D; Sehn LH; Savage KJ; Toze CL; Song K; den Brok WD; Freeman CL; Scott DW; Gerrie AS
Blood Adv; 2020 Aug; 4(15):3486-3494. PubMed ID: 32735654
[TBL] [Abstract][Full Text] [Related]
11. Estimating the Burden of Illness of Relapsed Follicular Lymphoma and Marginal Zone Lymphoma in Ontario, Canada.
Kuruvilla J; Ewara EM; Elia-Pacitti J; Ng R; Eberg M; Kukaswadia A; Sharma A
Curr Oncol; 2023 Apr; 30(5):4663-4676. PubMed ID: 37232810
[TBL] [Abstract][Full Text] [Related]
12. Adverse events, resource use, and economic burden associated with mantle cell lymphoma: a real-world assessment of privately insured patients in the United States.
Goyal RK; Nagar SP; Kabadi SM; Kaye JA; Seal B; Mato AR
Leuk Lymphoma; 2019 Apr; 60(4):955-963. PubMed ID: 30277099
[TBL] [Abstract][Full Text] [Related]
13. Bendamustine plus rituximab for previously untreated patients with indolent B-cell non-Hodgkin lymphoma or mantle cell lymphoma: a multicenter Phase II clinical trial in Japan.
Ogura M; Ishizawa K; Maruyama D; Uike N; Ando K; Izutsu K; Terui Y; Imaizumi Y; Tsukasaki K; Suzuki K; Izumi T; Usuki K; Kinoshita T; Taniwaki M; Uoshima N; Suzumiya J; Kurosawa M; Nagai H; Uchida T; Fukuhara N; Choi I; Ohmachi K; Yamamoto G; Tobinai K;
Int J Hematol; 2017 Apr; 105(4):470-477. PubMed ID: 27900638
[TBL] [Abstract][Full Text] [Related]
14. Superiority of ibrutinib plus bendamustine and rituximab in newly diagnosed patients with mantle-cell lymphoma ineligible for intensive therapy: A network meta-analysis.
Sheng Z; Wang L
Eur J Haematol; 2023 Jun; 110(6):602-607. PubMed ID: 36919283
[TBL] [Abstract][Full Text] [Related]
15. Bendamustine Plus Rituximab as Salvage Treatment for Patients with Relapsed or Refractory Low-grade B-cell Lymphoma and Mantle Cell Lymphoma: A Single-Center Retrospective Study.
Murakami H; Yoshioka T; Moriyama T; Ishikawa T; Makita M; Sunami K
Acta Med Okayama; 2021 Aug; 75(4):461-469. PubMed ID: 34511613
[TBL] [Abstract][Full Text] [Related]
16. Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes.
Castellino A; Wang Y; Larson MC; Maurer MJ; Link BK; Farooq U; Feldman AL; Syrbu SI; Habermann TM; Paludo J; Inwards DJ; Witzig TE; Ansell SM; Allmer C; Slager SL; Cohen JB; Martin P; Cerhan JR; Nowakowski GS
Blood Adv; 2022 Feb; 6(4):1350-1360. PubMed ID: 34662895
[TBL] [Abstract][Full Text] [Related]
17. Real World Treatment Practices for Mantle Cell Lymphoma in Japan: An Observational Database Research Study (CLIMBER-DBR).
Izutsu K; Suzumiya J; Takizawa J; Fukase K; Nakamura M; Jinushi M; Nagai H
J Clin Exp Hematop; 2021 Sep; 61(3):135-144. PubMed ID: 34092722
[TBL] [Abstract][Full Text] [Related]
18. Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma.
Telford C; Kabadi SM; Abhyankar S; Song J; Signorovitch J; Zhao J; Yao Z
Clin Ther; 2019 Nov; 41(11):2357-2379.e1. PubMed ID: 31699438
[TBL] [Abstract][Full Text] [Related]
19. Bendamustine and rituximab is well-tolerated and efficient in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma in elderly: A single center observational study.
Kotchetkov R; Drennan IR; Susman D; DiMaria E; Gerard L; Nay D; Prica A
Int J Cancer; 2023 May; 152(9):1884-1893. PubMed ID: 36545885
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial.
Kluin-Nelemans HC; Hoster E; Hermine O; Walewski J; Geisler CH; Trneny M; Stilgenbauer S; Kaiser F; Doorduijn JK; Salles G; Szymczyk M; Tilly H; Kanz L; Schmidt C; Feugier P; Thieblemont C; Zijlstra JM; Ribrag V; Klapper W; Pott C; Unterhalt M; Dreyling MH
J Clin Oncol; 2020 Jan; 38(3):248-256. PubMed ID: 31804876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]